Insights into the pharmacokinetic interactions between antimicrobial and antimalarial drugs following concurrent administration
Main Article Content
Abstract
Background: The co-administration of different drugs is imperative to achieve a desired therapeutic objective or treat coexisting diseases. For example, the concurrent use of antimicrobial and antimalarial drugs is common in the tropics because malaria is frequently associated with other infections such as those of the respiratory tract, urinary tract, or ear, sexually transmitted infections (STIs), and diarrhea, among other infections. Although numerous benefits can be derived from co-administration of different drugs, the expected therapeutic outcome is sometimes affected by drug-drug interactions.
Objective: The study of antimicrobial and antimalarial drug interactions is of great significance to both treatment and research. It is therefore worrying that the analysis of drug-interaction data is often inadequate, leading in some cases to false conclusions about synergism or antagonism. This review aimed to discuss recent findings on antimicrobial and antimalarial drug-drug interactions and some pitfalls in their analysis and interpretation.
Methods: Important literature databases such as Elsevier, IEEExplore, Pubmed, Scopus, Web of Science, Google Scholar, ProQuest, ScienceDirect, and BioMed Central were selected based on the quality, extant content, and broad area of the discipline. The specific keywords related to the study were identified and used for the study purposely to identify related works.
Results: Co-administration of two or more drugs is considered rational when trying to achieve a desired therapeutic objective or treat co-morbidities but the possibility of drug-drug interactions could offset these benefits by bringing about sub-therapeutic drug concentrations that could ultimately lead to treatment failure.
Conclusion: Patients, physicians, pharmacists, and other healthcare providers may be unaware of the possible interactions between antibiotics and antimalarials as well as the mechanisms involved. It is therefore common practice to co-administer antimalarial and antibiotic drugs. Caution is required with the co-administration of these medicines. It is also of public health concern, as the interactions can contribute towards observed antibiotic resistance and treatment failure being experienced in recommended antibiotic treatment regimens.
Downloads
Article Details
How to Cite
Share
References
Wilkinson GR. (2005). Drug metabolism and variability among patients in drug response. The
New England Journal of Medicine. 352(21):2211-2221.
Reygaert WC. (2018). An overview of the antimicrobial resistance mechanisms of bacteria.
AIMS Microbiol. 4:482-501.
Bruggemann RJM., Alffenaar JW., Blijlevens NMA., Billaud EM., Kosterink JG., Verweij PE., Burger DM.
(2008). Pharmacokinetic drug interactions of azoles. Curr. Fungal Infect. Rep. 22:20-27
Bassat, Q., Guinovart, C., Sigaúque, B., Mandomando, I., Aide, P., Sacarlal, J., and Alonso, P. L. (2009). Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Tropical Medicine and International Health, 14 (9): 1011-1019.
Butkiewicz M, Restrepo NA, Haines JL. and Crawford DC. (2016). Drug-Drug Interaction Profiles
of Medication Regimens Extracted from a DeIdentified Electronic Medical Records System. AMIA Jt Summits Transl Sci Proc. 33-40
Benet LZ, Hoener BA. (2002). Changes in plasma protein binding have little clinical relevance. Clinical
Pharmacology and Therapeutics. 71(3):115-21.
Taxak, K., and Bharatam, PV. (2010). An Insight into the Concept and Details of Mechanism-Based
Inhibition of CYP450. 11: 62-67.
Alemu, A., Shiferaw, Y., Addis, Z., Mathewos, B. and Birhan., W. (2013). Effect of malaria on HIV/AIDS
transmission and progression. Parasites and Vectors, 6 (1): 1-8.
Berkley, J., Mwarumba, S., Bramham, K., Lowe, B., and Marsh, K. (1999). Bacteraemia complicating
severe malaria in children. Transactions of the Royal Society of Tropical Medicine and Hygiene, 93 (3):
-286.
WHO, (2019). Essential Medicines and Health Products https://www.who.int/medicines/publications/essentialmedicines/en/ accessed 21/09/2023
Valadas, E., Gomes, A., Sutre, A., Brilha, S., Wete, A., and Hanscheid, T. (2013) Tuberculosis with malaria or HIV co-infection in a large hospital in Luanda, Angola. Journal of Infectious in Developing
Countries. 7: 269-272
Mohsen Heidary , Maryam Shirani , Melika Moradi , Mehdi Goudarzi , Ramin Pouriran , Tayebe Rezaeian ,Saeed Khoshnood 2022. Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.Eur Journal Microbiol Immunol (Bp) 12(1):1-17.
Baluku, JB., Sylvia, N., Brian, G., Namanda, M. Andia-Biraro, I., and Worodria, WPB. (2019).
"Prevalence of Malaria and TB Coinfection at a National Tuberculosis Treatment Centre in Uganda", Journal of Tropical Medicine, 3741294: 1- 7.
Mueller, AK., Behrends, J., Blank, J., Schaible, UE., and Schneider, BE. (2014). An experimental model
to study tuberculosis-malaria coinfection upon natural transmission of Mycobacterium tuberculosis and Plasmodium berghei. JoVE (Journal of Visualized Experiments), (84), e50829.
Kong DC., Wu HY., Zheng YX., H Pan , CY Jiang , X Zhang, J Chen, F Wu (2019). Etiologic and
epidemiologic features of acute respiratory infections in adults from Shanghai, during 2015-
Zhonghua Liu Xing Bing Xue Za Zhi Chinese. 10(8):904-910.
Egan, TJ. (2001). Structure-function relationships in chloroquine and related 4-aminoquinoline
antimalarials. Mini Reviews in Medicinal Chemistry, 1(1), 113-123
M. Birhanie, B. Tessema, G. Ferede, M. Endris, B. Enawgaw. Malaria, typhoid fever, and their coinfection among febrile patients at a rural health center in Northwest Ethiopia: a cross-sectional
study. Adv Med, 2014 (2014), p. 531074
Etienne PA., Neve, Magnus Ingelman-Sundberg 2010. Cytochrome P450 proteins: retention and
distribution from the endoplasmic reticulum. Current Opinion in Drug Discovery and Development
(1):78-85.
Winstanley PA., Coleman JW., Maggs JL., Breckenridge AM., Park BK. (1990). The toxicity of
amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte/monocyte colony forming units. Br. Journal Clin Pharmacol 29(4):479-485.
Li X. Q., Björkman A., Andersson TB., Ridderström M, Masimirembwa CM. (2002). Amodiaquine
clearance and its metabolism to N-Desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. Journal Pharmacol Exp Ther. 300(2):399-407.
Parikh S, Ouedraogo JB., Goldstein JA., Rosenthal P. J., Kroetz DL. (2007). Amodiaquine metabolism is
impaired by common polymorphisim in CYP2C8: implications for malaria treatment in Africa. Clin
Pharmacol Ther. 82(2):197-203.
Alexandra T. Roux, Leah Maharaj, Olukunle Oyegoke Oluwasegun P. Akoniyon , Matthew
Adekunle Adeleke, Rajendra Maharaj, Moses Okpeku (2021). Chloroquine and SulfadoxinePyrimethamine Resistance in Sub-Saharan Africa-A Review. Sec. Evolutionary and Genomic
Microbiology. Frontiers in Genetics. 12
Adebusuyi Akande Ademisoye, Julius Olugbenga Soyinka, Samuel Olanrewaju Olawoye1, Sharon
Iyobor Igbinoba, Samuel Anu Olowookere, Adelola Taiwo Ademisoye and Cyprian Ogbona Onyeji
(2018). Induction of Amodiaquine Metabolism by Rifampicin Following Concurrent Administration in
Healthy Volunteers. Journal of Exploratory Research in Pharmacology. 3 | 71-77
Church, JA., Fitzgerald, F., Walker, AS., Gibb, DM., & Prendergast, A. J. (2015). The expanding role of cotrimoxazole in developing countries. The Lancet Infectious Diseases, 15(3), 327-339.
Ademisoye AA, Soyinka JO, Abdullahi ST, and Onyeji CO (2015). Effects of co-trimoxazole coadministration on the pharmacokinetics of amodiaquine in healthy volunteers. International
Journal Pharm Pharm Sci 7(9):272-276.
Ward BA, Gorski JC, Jones DR, Hall SD, Flockhat DA, Desta Z (2003). The cytochrome P 450 2B6 is the
main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and
utility of efavirenz as a substrate marker of CYP 2B6 catalytic activity. Journal Pharmacol Exp Ther.
:287e300
Julius O. Soyinka, Cyprian O. Onyeji, Thomas I. Nathaniel, Olugbenga O. Odunfa Benjamin U.
Ebeshi (2013). Effects of concurrent administration of efavirenz on the disposition kinetics of
amodiaquine in healthy volunteers. Journal of Pharmacy Research 6: 275 e279
Adam I, Ali DM, Noureldin W, Elbashir MI (2005). Quinine for treatment of chloroquine-resistant
falciparum malaria in pregnant and non-pregnant Sudanese women. Ann Trop Med Parasito.l 99: 427-
Sanjeev K, Nelamangala V, Tim P, Tsiri A, Peter W (2001). Population pharmacokinetics of
intramuscular quinine in children with severe malaria. Antimicrob Agents Chemother 45: 1803-9.
PrayGod G, Albie F, Eisenhurt M (2008). Artemisinin derivative versus quinine in treating severe malaria in children: a systematic review. Malaria Journal. 7: 210.
Hooper DC (2000). New uses for new and old quinolones and the challenge of resistance. Clin
Infect Dis. 30:243- 254.
Mohsen AH, Dalia RE, Gamal ME (2005). The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. Bull Pharm Sci (Assiut University). 28:137-142.
Adebanjo J. Adegbola, Julius O. Soyinka, Babatunde A. Adeagbo, Sharon I. Igbinoba, and Thomas I.
Nathaniel (2016). Alteration of the Disposition of Quinine in Healthy Volunteers After Concurrent
Ciprofloxacin Administration. American Journal of Therapeutics 23: e398-e404
Back D et al. (2003). Pharmacokinetic drug interactions with nevirapine. Acquir Immune Defic
Syndr 2003; 14(Suppl): 591-600.
Erickson DA et al. (1999). Characterization of the in vitro biotransformation of the HIV-1 reverse
transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 27: 1488-
Julius O. Soyinka, Cyprian O. Onyeji, Sharon I. Omoruyi, Adegbenga R. Owolabi, Pullela V. Sarma
and James M. Cook (2009). Effects of concurrent administration of nevirapine on the disposition of
quinine in healthy volunteers. Journal of Pharmacy and Pharmacology. 61: 439-443
Hsu A, Granneman R, Bertz RJ (1998). Ritonavir: clinical pharmacokinetics and interactions with
other anti-HIV agents. Clin Pharmacokinet. 35: 275-91.
Profit L, Eagling VA, Back DJ (1999). Modulation of Pglycoprotein function in human lymphocytes and Caca-2 cells monolayers by HIV-1 protease inhibitors. AIDS 13:1623-7.
Julius O. Soyinka, Cyprian O. Onyeji, Sharon I. Omoruyi, Adegbenga R. Owolabi, Pullela V. Sarma
and James M. Cook (2009). Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br. Journal Clin Pharmacol 69:3 262-
World Health Organization, 2001. The Use of Antimalarial Drugs: Report of a WHO Informal
Consultation. WHO, Geneva, November 13-17, 2000.
Pauline Byakika-Kibwika, Mohammed Lamorde, Jonathan Mayito, Lillian Nabukeera, Rhoda
Namakula, Harriet Mayanja-Kizza, Elly Katabira et al. (2012). Significant pharmacokinetic interactions
between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Journal Antimicrob Chemother. 67(9): 2213-2221.
Barry, M., Gibbons, S., Mulcahy, F., Merry, C., Back, D., (1999). Pharmacokinetics and potential
interactions amongst antiretroviral agents used to treat patients with HIV infections. Clin. Pharmacokinet. 36, 289-304.
Walimbwa, Mohammed Lamorde, Catriona Waitt, Julian Kaboggoza, Laura Else, Pauline Byakikaibwika, Alieu Amara, Joshua Gini, Markus Winterberg, Justin Chiong, Saye H. Khoo (2016).
Drug Interactions between Dolutegravir and Artemether-Lumefantrine or ArtesunateAmodiaquine. Antimicrobial Agents and Chemotherapy. 63: 2. 12 -18.
Srivastava, KI., Vaidya, AB., (1999). A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother. 43, 1334-1339.
Helsby, NA., Ward, SA., Edwards, IG., Howells, RE., Breckenrige, A.M., (1990). The pharmacokinetics
and activation of proguanil in man: consequences of variability in drug metabolism. Br. Journal Clin.
Pharmacol. 30, 593-598.
Nwokolo, C., Wambebe, C., Akinyanju, O., Raji, AA., Audu, BS., Emodi, IJ., Balogun, MO., Chukwuani,
CM., (2001). Mefloquine versus proguanil in shortterm malaria chemoprophylaxis in sickle cell anaemia. Clin. Drug Invest. 21 (8), 537-544.
Julius Olugbenga Soyinka, and Cyprian Ogbonna Onyeji (2010). Alteration of pharmacokinetics of
proguanil in healthy volunteers following concurrent administration of efavirenz. European
Journal of Pharmaceutical Sciences 39: 213-218.